Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Singer Yoon Bok-hee (79) reported the sad news that she lost her sight in one eye. He revealed this in an interview conducted ...

Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its ophthalmology programs including development of new treatment options for retinopathies. Other ...

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the ...

Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release.

Opthea said it agreed with the investors in its development funding agreement to end development of sozinibercept in wet AMD, and that the move wouldn't constitute a termination event under the ...

The decision to discontinue the trials comes shortly after the announcement that COAST missed its primary endpoint.

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

Acer Medical has recently launched its AI-assisted screening software, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration. These innovative solutions will be showcased at the ...

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...